Gilead bets $1.68B upfront on UCLA Bioengineering Alumni’s Ouro Medicines’ autoimmune program, with Galapagos expected to pitch in

Gilead Sciences is set to enter the T cell engager space in an unusual — perhaps even unprecedented — deal arrangement that involves the pharma budgeting about $1.68 billion upfront to buy Ouro...
Implantable “Charging Station” Boosts Fight Against Cancer

Implantable “Charging Station” Boosts Fight Against Cancer

Mar 17, 2026 UCLA Samueli Newsroom Immunotherapy has transformed cancer treatment by harnessing the body’s own immune system to fight disease. But many engineered immune cells lose strength quickly after they enter the body, especially inside tumors that actively...

Bioengineering Students Named to the 2025 Highly Cited Researchers List

Bioengineering Students Named to the 2025 Highly Cited Researchers List

On Nov. 12 2025, in the 2025 edition of Clarivate’s Highly Cited Researchers list—which recognised 6,868 researchers worldwide across more than 1,300 institutions in 60 countries with 7,131 awards—UCLA Bioengineering post-doctoral researcher Yihao Zhou and PhD student...

Dynamic and Soft Cell Surroundings Shape Cell Identity

Dynamic and Soft Cell Surroundings Shape Cell Identity

Oct 24, 2025 UCLA Samueli Newsroom AUCLA-led research team has discovered that the viscoelasticity of a cell’s surroundings — the property that allows them to harden and soften as they deform and relax under stress over time — can influence how the cell’s genetic...